PCSK9在非酒精性脂肪性肝病中的作用  

Roles of PCSK9 in non-alcoholic fatty liver disease

作　　者：成璐 柯柏怡 王宗保 王姝之 CHENG Lu;KE Boyi;WANG Zongbao;WANG Shuzhi(Institute of Pharmacy and Pharmacology,School of Pharmaceutical Science,Hunan Collaborative Innovation Center of Molecular Target New Drug Research,University of South China,Hengyang 421001,China)

机构地区：[1]南华大学药学院药物药理研究所,湖南省分子靶标新药研究协同创新中心,衡阳421001

出　　处：《生命的化学》2022年第12期2157-2164,共8页Chemistry of Life

基　　金：湖南省教育厅科学研究项目(20K106);湖南省卫生健康委科研项目(D202302048902)

摘　　要：近年来,非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)的发病率逐年上升。作为多种脂质代谢性疾病的重要影响因素,NAFLD预防和治疗迫在眉睫。原蛋白转化酶枯草杆菌素9(preprotein convertase subtilisin/kexin 9,PCSK9,一种内源性蛋白酶)具有调控NAFLD发生发展的作用,但其对肝脏脂质代谢的潜在影响和作用机制尚未完全阐明。本文就PCSK9在NAFLD领域的研究进展进行综述,阐述PCSK9的生物学功能和在脂质代谢和炎症反应中的作用机制,为以PCSK9为靶点防治NAFLD及预后评估提供理论依据。In recent years,the incidence of nonalcoholic fatty liver disease(NAFLD)has increased rapidly.As an important factor affecting a variety of lipid metabolic diseases,the prevention and treatment of NAFLD is urgent.Preprotein convertase subtilisin/kexin 9(PCSK9)is an endogenous protease that regulates the occurrence and development of NAFLD.However,the potential effects and mechanism of PCSK9 in liver lipid metabolism have not been fully elucidated.The role of PCSK9 in NAFLD requires further investigation.In this review,we focus on the impact of PCSK9 on the development of NAFLD.

关 键 词：原蛋白转化酶枯草杆菌素9 非酒精性脂肪性肝病 脂质代谢 

分 类 号：R575.5[医药卫生—消化系统]